查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1833575

2032年肠外抗生素市场预测：按药物类别、活性频谱、剂型、给药途径、适应症、最终用户和地区进行的全球分析

Parenteral Antibiotics Market Forecasts to 2032 - Global Analysis By Drug Class, Spectrum of Activity, Formulation Type, Route of Administration, Indication, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球肠外抗生素市场预计在 2025 年达到 257.4 亿美元，到 2032 年将达到 394.8 亿美元，预测期内的复合年增长率为 6.3%。

肠外抗生素是指在消化器官系统外给药的药物，通常透过静脉注射、肌肉注射或皮下注射。它们适用于紧急治疗以及无法口服或胃肠道吸收不足的情况。这种方法将药物直接输送到血液中，从而具有更快的起效速度、更高的生物利用度，并能有效感染疾病需要即时干预的严重或广泛性感染疾病。

根据尼泊尔国家生物技术资讯中心 (NCBI) 2021 年 11 月发表的一项研究，2019 年尼泊尔肠外抗生素的总限定日剂量 (DDD) 达到 48,947.7，比 2017 年的 39,639.7 增长了 23%。

抗生素抗药性（AMR）的蔓延

随着病原体不断进化并对传统疗法产生抗药性，医疗保健提供者正转向注射剂以获得更快、更有效的治疗效果。这一趋势在医院环境中尤其明显，因为医院环境中存在多重抗药性感染。药物输送系统和製剂科学的技术进步正在提高肠外抗生素的有效性。精准医疗和特异性病原体的治疗的兴起进一步推动了市场成长。全球卫生组织也将降低抗生素抗药性作为优先事项，并推动对新型抗生素和管理计画的投资。

开发和商业化成本高

大规模临床试验、严格的安全规程以及遵守FDA和EMA法规等全球标准，导致开发週期更长、成本更高。脂质体和缓释性等先进技术的采用，也让核准流程更加复杂。规模较小的製药公司往往面临资源限制，这限制了其创新和扩大生产规模的能力。此外，低温运输物流和无菌包装的需求也增加了营运成本。这些因素共同阻碍了药物快速进入市场，并减缓了治疗方法创新的步伐。

扩大门诊肠外抗生素治疗（OPAT）

门诊肠外抗生素治疗 (OPAT) 的推广为市场开闢了新的成长途径。 OPAT 允许患者在院外接受抗生素输注，从而减轻住院负担和医疗费用。携带式输注设备和远端监控技术的进步使 OPAT 更加便利和安全。医疗保健系统正在采用分散式照护模式，家庭治疗越来越受欢迎。报销改革和临床指南正在支持将 OPAT 纳入主流医疗。这种转变推动了对易于使用、稳定、长效且专为门诊病人设计的肠外抗生素製剂的需求。

与学名药的竞争加剧

专利到期和生物相似药开发的监管激励措施正在加速学名药的进入。学名药学名药蓬勃发展，加剧了竞争动态。为了维持市场份额，新药公司必须投资生命週期管理策略，例如配方改进和联合治疗。

COVID-19的影响：

新冠疫情严重扰乱了肠外抗生素市场格局，改变了需求模式和供应链运作。儘管择期手术被推迟，医院抗生素使用量减少，但重症监护室（ICU）入院人数激增，导致频谱注射剂的需求增加。生产延误和全球物流瓶颈导致关键抗生素暂时短缺。然而，这场危机加速了数位医疗的普及，包括远距处方和基于远端医疗的OPAT计画。监管机构推出了紧急途径，以确保快速核准和药品供应。疫情后的復苏目前专注于建立韧性供应链和扩展分散式医疗模式。

青霉素类药物预计将成为预测期内最大的药物

青霉素类抗生素因其广泛的疗效和成熟的临床效用，预计将在预测期内占据最大的市场份额。这些抗生素广泛用于治疗感染疾病、皮肤和尿道感染，尤其适用于住院患者。製剂稳定性和给药便捷性的不断改进巩固了其市场领先地位。频谱青霉素类抗生素与β-内酰胺酶抑制剂的联合应用增强了抗药性因应措施。青霉素类抗生素因其安全性和成本效益而受到医院的青睐，尤其是在团体治疗中。新兴趋势包括双药组合方案和纳入OPAT方案。

预计门诊手术中心部分在预测期内的复合年增长率最高

预计在预测期内，门诊手术中心细分市场将实现最高成长率，这得益于手术全期。智慧型输液系统与云端基础库存追踪的整合正在简化抗生素的管理。优惠的报销政策和更短的患者住院时间正在推动门诊手术中心的利用率。向微创手术的转变正在增加对速效注射抗生素的需求。紧凑型抗生素套件和单剂量包装的创新正根据门诊手术中心的工作流程进行客製化。

占比最大的地区：

受医疗基础设施扩张和感染率上升的推动，亚太地区预计将在预测期内占据最大的市场份额。中国、印度和印尼等国家正在投资建立医院容量和抗生素生产能力。政府推动本地生产和抗生素管理的措施正在推动市场扩张。该地区的都市区地区都正在迅速普及注射疗法。全球製药公司与本地公司之间的策略合作伙伴关係正在加强分销和技术转移。新兴趋势包括人工智慧诊断和服务欠缺地区的行动门诊治疗单位 (OPAT)。

复合年增长率最高的地区：

在技​​术创新和强劲医疗支出的推动下，北美预计将在预测期内呈现最高的复合年增长率。美国和加拿大在新型肠外抗生素製剂（例如基于脂质体和奈米颗粒的注射剂）的开发方面处于领先地位。监管机构正在简化重要抗生素的核准途径，以加快其市场准入速度。医院正在整合电子处方和智慧输液泵，以优化抗生素给药。该地区受益于强大的报销框架和对抗菌药物抗药性挑战的高度认知。随着个人化医疗和门诊治疗的扩展，北美正处于抗生素创新的前沿。

免费客製化服务：

此报告的订阅者可以选择以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球肠外抗生素市场（依药物类别）

  • 青霉素
  • 大环内酯类
  • 头孢菌素类
  • 糖肽
  • 卡巴培南类
  • Aminoglycosides
  • 其他药物类别

6. 全球肠外抗生素市场（依活性频谱）

  • 频谱抗生素
  • 窄效抗生素

7. 全球肠外抗生素市场（按剂型）

  • 单剂量管瓶
  • 多剂量管瓶
  • 点滴袋
  • 预填充式注射器

8. 全球肠外抗生素市场（依给药途径）

  • 静脉注射（IV）
  • 皮下（SC）
  • 肌肉注射（IM）

9. 全球肠外抗生素市场（按适应症）

  • 呼吸道感染疾病
  • 尿道感染
  • 皮肤和软组织感染疾病
  • 院内感染
  • 腹腔内感染疾病
  • 手术部位感染
  • 败血症和血流感染疾病
  • 其他适应症

10. 全球肠外抗生素市场（依最终用户）

  • 医院
  • 家庭医疗保健
  • 专科诊所
  • 门诊手术中心
  • 其他最终用户

11. 全球肠外抗生素市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：企业概况

  • Pfizer Inc.
  • Sandoz
  • Merck & Co., Inc.
  • Spero Therapeutics
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • GlaxoSmithKline plc
  • Entasis Therapeutics
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Bristol-Myers Squibb
  • Bayer AG
  • Eli Lilly and Company
  • Abbott Laboratories
Product Code: SMRC31408

According to Stratistics MRC, the Global Parenteral Antibiotics Market is accounted for $25.74 billion in 2025 and is expected to reach $39.48 billion by 2032 growing at a CAGR of 6.3% during the forecast period. Parenteral antibiotics refer to drugs given outside the digestive system, commonly via intravenous, intramuscular, or subcutaneous injection. They are preferred for urgent treatment, cases where oral intake is not feasible, or when gastrointestinal absorption is inadequate. This method delivers the medication directly into the bloodstream, providing rapid action, greater bioavailability, and effective management of serious or widespread infections requiring immediate intervention.

According to a study published in National Canter for Biotechnology Information (NCBI) in November 2021, in Nepal, the total defined daily dose (DDD) of parenteral antibiotics reached 48,947.7 in 2019 with an increase of 23% from 39,639.7 in 2017.

Market Dynamics:

Driver:

Growing antimicrobial resistance (AMR)

As pathogens evolve and become resistant to conventional treatments, healthcare providers are turning to injectable formulations for faster and more effective outcomes. This trend is especially pronounced in hospital settings where multidrug-resistant infections are prevalent. Technological advancements in drug delivery systems and formulation science are enhancing the efficacy of parenteral antibiotics. The rise of precision medicine and pathogen-specific therapies is further boosting market growth. Global health agencies are also prioritizing AMR mitigation, driving investment in novel antibiotic classes and stewardship programs.

Restraint:

High cost of development and commercialization

Extensive clinical trials, stringent safety protocols, and compliance with global standards like FDA and EMA regulations contribute to prolonged timelines and elevated costs. Incorporating advanced technologies such as liposomal delivery and extended-release mechanisms adds complexity to the approval process. Smaller pharmaceutical firms often face resource constraints, limiting their ability to innovate or scale production. Additionally, the need for cold chain logistics and sterile packaging increases operational expenses. These factors collectively hinder rapid market entry and slow down the pace of therapeutic innovation.

Opportunity:

Growing outpatient parenteral antibiotic therapy (OPAT)

The expansion of outpatient parenteral antibiotic therapy (OPAT) is unlocking new growth avenues for the market. OPAT enables patients to receive intravenous antibiotics outside hospital settings, reducing inpatient burden and healthcare costs. Advances in portable infusion devices and remote monitoring technologies are making OPAT more accessible and safer. Healthcare systems are increasingly adopting decentralized care models, with home-based treatments gaining traction. Reimbursement reforms and clinical guidelines are supporting OPAT integration into mainstream care. This shift is driving demand for user-friendly, stable, and long-acting parenteral antibiotic formulations tailored for outpatient use.

Threat:

Increased competition from generics

Patent expirations and regulatory incentives for biosimilar development are accelerating generic entry. While generics improve accessibility, they also compress profit margins for originator companies. Technological parity in manufacturing and formulation is narrowing the differentiation gap. Emerging markets are witnessing a surge in local generic production, intensifying competitive dynamics. To maintain market share, innovators must invest in lifecycle management strategies, such as reformulations and combination therapies.

Covid-19 Impact:

The COVID-19 pandemic significantly disrupted the parenteral antibiotics landscape, altering demand patterns and supply chain operations. Elective procedures were postponed, reducing hospital-based antibiotic usage, while ICU admissions surged, increasing demand for broad-spectrum injectables. Manufacturing delays and global logistics bottlenecks led to temporary shortages of critical antibiotics. However, the crisis accelerated digital health adoption, including remote prescribing and telemedicine-based OPAT programs. Regulatory bodies introduced emergency pathways to fast-track approvals and ensure drug availability. Post-pandemic recovery is now focused on building resilient supply chains and expanding decentralized treatment models.

The penicillinssegment is expected to be the largest during the forecast period

The penicillinssegment is expected to account for the largest market share during the forecast period, due to its broad-spectrum efficacy and established clinical utility. These antibiotics are widely used in treating respiratory, skin, and urinary tract infections, especially in inpatient settings. Continuous improvements in formulation stability and dosing convenience are reinforcing their market leadership. The development of extended-spectrum penicillins and beta-lactamase inhibitor combinations is enhancing resistance management. Hospitals favor penicillins for their safety profile and cost-effectiveness, particularly in high-volume treatment scenarios. Emerging trends include dual-drug regimens and integration into OPAT protocols.

The ambulatory surgical centerssegment is expected to have the highest CAGR during the forecast period

Over the forecast period, the ambulatory surgical centerssegment is predicted to witness the highest growth rate, driven by the rise in outpatient procedures. ASCs are increasingly performing complex surgeries that require perioperative antibiotic prophylaxis. Integration of smart infusion systems and cloud-based inventory tracking is streamlining antibiotic administration. Favorable reimbursement policies and shorter patient stays are boosting ASC utilization. The shift toward minimally invasive techniques is increasing demand for rapid-acting injectable antibiotics. Innovations in compact antibiotic kits and single-dose packaging are tailored for ASC workflows.

Region with largest share:

During the forecast period, the Asia Pacificregion is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising infection rates. Countries like China, India, and Indonesia are investing in hospital capacity and antibiotic manufacturing capabilities. Government initiatives promoting local production and antimicrobial stewardship are fueling market expansion. The region is witnessing rapid adoption of injectable therapies in both urban and rural settings. Strategic collaborations between global pharmaceutical firms and regional players are enhancing distribution and technology transfer. Emerging trends include AI-assisted diagnostics and mobile OPAT units in underserved areas.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by technological innovation and robust healthcare spending. The U.S. and Canada are leading in the development of novel parenteral antibiotic formulations, including liposomal and nanoparticle-based injectables. Regulatory agencies are streamlining approval pathways for critical antibiotics, encouraging faster market entry. Hospitals are integrating electronic prescribing and smart infusion pumps to optimize antibiotic delivery. The region benefits from strong reimbursement frameworks and high awareness of AMR challenges. As personalized medicine and outpatient care expand, North America remains at the forefront of antibiotic innovation.

Key players in the market

Some of the key players in Parenteral Antibiotics Market include Pfizer Inc., Sandoz, Merck & Co., Inc., Spero Therapeutics, Johnson & Johnson, AstellasPharma Inc., GlaxoSmithKline plc, Entasis Therapeutics, Sanofi, F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb, Bayer AG, Eli Lilly and Company, and Abbott Laboratories.

Key Developments:

In September2025, Pfizer Inc. and Metsera, Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portfolio of differentiated oral and injectable incretin, non-incretin and combination therapy candidates with potential best-in-class efficacy and safety profiles.

In February2025, Shedd Aquarium and global healthcare company Abbott are announcing one of Shedd's largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.

Drug Classes Covered:

  • Penicillins
  • Macrolides
  • Cephalosporins
  • Glycopeptides
  • Carbapenems
  • Aminoglycosides
  • Other Drug Classes

Spectrum of Activities Covered:

  • Broad-Spectrum Antibiotics
  • Narrow-Spectrum Antibiotics

Formulation Types Covered:

  • Single-Dose Vials
  • Multi-Dose Vials
  • Infusion Bags
  • Pre-filled Syringes

Route of Administrations Covered:

  • Intravenous (IV)
  • Subcutaneous (SC)
  • Intramuscular (IM)

Indications Covered:

  • Respiratory Infections
  • Urinary Tract Infections
  • Skin and Soft Tissue Infections
  • Hospital-Acquired Infections
  • Intra-abdominal Infections
  • Surgical Site Infections
  • Sepsis and Bloodstream Infections
  • Other Applications

End Users Covered:

  • Hospitals
  • Home Healthcare
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Parenteral Antibiotics Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Penicillins
  • 5.3 Macrolides
  • 5.4 Cephalosporins
  • 5.5 Glycopeptides
  • 5.6 Carbapenems
  • 5.7 Aminoglycosides
  • 5.8 Other Drug Classes

6 Global Parenteral Antibiotics Market, By Spectrum of Activity

  • 6.1 Introduction
  • 6.2 Broad-Spectrum Antibiotics
  • 6.3 Narrow-Spectrum Antibiotics

7 Global Parenteral Antibiotics Market, By Formulation Type

  • 7.1 Introduction
  • 7.2 Single-Dose Vials
  • 7.3 Multi-Dose Vials
  • 7.4 Infusion Bags
  • 7.5 Pre-filled Syringes

8 Global Parenteral Antibiotics Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Intravenous (IV)
  • 8.3 Subcutaneous (SC)
  • 8.4 Intramuscular (IM)

9 Global Parenteral Antibiotics Market, By Indication

  • 9.1 Introduction
  • 9.2 Respiratory Infections
  • 9.3 Urinary Tract Infections
  • 9.4 Skin and Soft Tissue Infections
  • 9.5 Hospital-Acquired Infections
  • 9.6 Intra-abdominal Infections
  • 9.7 Surgical Site Infections
  • 9.8 Sepsis and Bloodstream Infections
  • 9.9 Other Applications

10 Global Parenteral Antibiotics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Home Healthcare
  • 10.4 Specialty Clinics
  • 10.5 Ambulatory Surgical Centers
  • 10.6 Other End Users

11 Global Parenteral Antibiotics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Pfizer Inc.
  • 13.2 Sandoz
  • 13.3 Merck & Co., Inc.
  • 13.4 Spero Therapeutics
  • 13.5 Johnson & Johnson
  • 13.6 Astellas Pharma Inc.
  • 13.7 GlaxoSmithKline plc
  • 13.8 Entasis Therapeutics
  • 13.9 Sanofi
  • 13.10 F. Hoffmann-La Roche Ltd
  • 13.11 Novartis AG
  • 13.12 Bristol-Myers Squibb
  • 13.13 Bayer AG
  • 13.14 Eli Lilly and Company
  • 13.15 Abbott Laboratories

List of Tables

  • Table 1 Global Parenteral Antibiotics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Parenteral Antibiotics Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Parenteral Antibiotics Market Outlook, By Penicillins (2024-2032) ($MN)
  • Table 4 Global Parenteral Antibiotics Market Outlook, By Macrolides (2024-2032) ($MN)
  • Table 5 Global Parenteral Antibiotics Market Outlook, By Cephalosporins (2024-2032) ($MN)
  • Table 6 Global Parenteral Antibiotics Market Outlook, By Glycopeptides (2024-2032) ($MN)
  • Table 7 Global Parenteral Antibiotics Market Outlook, By Carbapenems (2024-2032) ($MN)
  • Table 8 Global Parenteral Antibiotics Market Outlook, By Aminoglycosides (2024-2032) ($MN)
  • Table 9 Global Parenteral Antibiotics Market Outlook, By Other Drug Classes (2024-2032) ($MN)
  • Table 10 Global Parenteral Antibiotics Market Outlook, By Spectrum of Activity (2024-2032) ($MN)
  • Table 11 Global Parenteral Antibiotics Market Outlook, By Broad-Spectrum Antibiotics (2024-2032) ($MN)
  • Table 12 Global Parenteral Antibiotics Market Outlook, By Narrow-Spectrum Antibiotics (2024-2032) ($MN)
  • Table 13 Global Parenteral Antibiotics Market Outlook, By Formulation Type (2024-2032) ($MN)
  • Table 14 Global Parenteral Antibiotics Market Outlook, By Single-Dose Vials (2024-2032) ($MN)
  • Table 15 Global Parenteral Antibiotics Market Outlook, By Multi-Dose Vials (2024-2032) ($MN)
  • Table 16 Global Parenteral Antibiotics Market Outlook, By Infusion Bags (2024-2032) ($MN)
  • Table 17 Global Parenteral Antibiotics Market Outlook, By Pre-filled Syringes (2024-2032) ($MN)
  • Table 18 Global Parenteral Antibiotics Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 19 Global Parenteral Antibiotics Market Outlook, By Intravenous (IV) (2024-2032) ($MN)
  • Table 20 Global Parenteral Antibiotics Market Outlook, By Subcutaneous (SC) (2024-2032) ($MN)
  • Table 21 Global Parenteral Antibiotics Market Outlook, By Intramuscular (IM) (2024-2032) ($MN)
  • Table 22 Global Parenteral Antibiotics Market Outlook, By Indication (2024-2032) ($MN)
  • Table 23 Global Parenteral Antibiotics Market Outlook, By Respiratory Infections (2024-2032) ($MN)
  • Table 24 Global Parenteral Antibiotics Market Outlook, By Urinary Tract Infections (2024-2032) ($MN)
  • Table 25 Global Parenteral Antibiotics Market Outlook, By Skin and Soft Tissue Infections (2024-2032) ($MN)
  • Table 26 Global Parenteral Antibiotics Market Outlook, By Hospital-Acquired Infections (2024-2032) ($MN)
  • Table 27 Global Parenteral Antibiotics Market Outlook, By Intra-abdominal Infections (2024-2032) ($MN)
  • Table 28 Global Parenteral Antibiotics Market Outlook, By Surgical Site Infections (2024-2032) ($MN)
  • Table 29 Global Parenteral Antibiotics Market Outlook, By Sepsis and Bloodstream Infections (2024-2032) ($MN)
  • Table 30 Global Parenteral Antibiotics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 31 Global Parenteral Antibiotics Market Outlook, By End User (2024-2032) ($MN)
  • Table 32 Global Parenteral Antibiotics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 33 Global Parenteral Antibiotics Market Outlook, By Home Healthcare (2024-2032) ($MN)
  • Table 34 Global Parenteral Antibiotics Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 35 Global Parenteral Antibiotics Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 36 Global Parenteral Antibiotics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.